GMED vs RARE
Globus Medical vs Ultragenyx Pharmaceutical Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
RARE
Ultragenyx Pharmaceutical Inc.
56
Watch
| Metric | GMED | RARE |
|---|
| AI Score |
71
|
56
|
| Price |
$85.12
|
$26.96
|
| P/E Ratio |
21.45×
|
-4.62×
|
| ROE |
11.8%
|
718.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
83.1%
|
| Debt / Equity |
0.02×
|
-4.13×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
54.3
|
| Beta |
0.954
|
0.313
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus RARE.
GMED leads by 15 points.
GMED scores 71/100 (Buy) versus RARE at 56/100 (Watch).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
RARE Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 27.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
- Bollinger bandwidth of 27.5% signals elevated volatility — Risk